JP2014532706A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532706A5
JP2014532706A5 JP2014540059A JP2014540059A JP2014532706A5 JP 2014532706 A5 JP2014532706 A5 JP 2014532706A5 JP 2014540059 A JP2014540059 A JP 2014540059A JP 2014540059 A JP2014540059 A JP 2014540059A JP 2014532706 A5 JP2014532706 A5 JP 2014532706A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532706A (ja
JP6117225B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062929 external-priority patent/WO2013067098A1/en
Publication of JP2014532706A publication Critical patent/JP2014532706A/ja
Publication of JP2014532706A5 publication Critical patent/JP2014532706A5/ja
Application granted granted Critical
Publication of JP6117225B2 publication Critical patent/JP6117225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540059A 2011-11-02 2012-11-01 抗kdr抗体およびその使用方法 Active JP6117225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161554758P 2011-11-02 2011-11-02
US61/554,758 2011-11-02
US201261609581P 2012-03-12 2012-03-12
US61/609,581 2012-03-12
PCT/US2012/062929 WO2013067098A1 (en) 2011-11-02 2012-11-01 Anti-kdr antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2014532706A JP2014532706A (ja) 2014-12-08
JP2014532706A5 true JP2014532706A5 (enExample) 2015-11-19
JP6117225B2 JP6117225B2 (ja) 2017-04-19

Family

ID=48192738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540059A Active JP6117225B2 (ja) 2011-11-02 2012-11-01 抗kdr抗体およびその使用方法

Country Status (12)

Country Link
US (1) US9441042B2 (enExample)
EP (1) EP2785742B1 (enExample)
JP (1) JP6117225B2 (enExample)
KR (1) KR102027603B1 (enExample)
AU (1) AU2012318246B2 (enExample)
BR (1) BR112014010774A2 (enExample)
CA (1) CA2854153A1 (enExample)
IL (1) IL232383B (enExample)
MX (1) MX356412B (enExample)
RU (1) RU2014122184A (enExample)
TW (1) TWI571473B (enExample)
WO (1) WO2013067098A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법
CN107531785B (zh) 2014-10-07 2021-06-29 卡德门企业有限公司 人抗-vegfr-2/kdr抗体
KR101896882B1 (ko) * 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
CN109952315A (zh) * 2016-11-16 2019-06-28 伊莱利利公司 用于转移性结直肠癌的治疗
CN110959013A (zh) * 2017-06-22 2020-04-03 埃派斯进有限公司 抗vista抗体和使用方法
CN114174335B (zh) * 2019-07-19 2023-12-15 神州细胞工程有限公司 一种人源化vegfr2抗体及其应用
JP2024517600A (ja) * 2021-04-14 2024-04-23 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗hVEGFR2抗体
KR20230039943A (ko) * 2021-09-15 2023-03-22 주식회사 파멥신 항-vegfr2(kdr) 개량 항체 및 이의 용도

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법
RU2002129574A (ru) 2000-03-31 2004-04-20 Имклон Системс Инкорпорейтед (Us) Лечение неплотных опухолей молочной железы антагонистами рецепторов сосудистого эндотелиального фактора роста
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
ES2362931T3 (es) 2002-03-04 2011-07-15 Imclone Llc Anticuerpos humanos específicos contra kdr y usos de los mismos.
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー/エス 組換え一価抗体およびその作製方法
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
US20100317539A1 (en) 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) * 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2014532706A5 (enExample)
CN106659779B (zh) 双特异性四价抗体及其制造和使用方法
TWI899079B (zh) 抗ror1/抗cd3雙特異性結合分子
JP2017535257A5 (enExample)
JP2014518615A5 (enExample)
JP2013527761A5 (enExample)
JP2018503380A5 (enExample)
RU2014122184A (ru) Антитела к kdr и способы их применения
JP2014503189A5 (enExample)
JP2013506428A5 (enExample)
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
IL273424B2 (en) Novel bispecific cd3/cd19 polypeptide complexes
RU2016136527A (ru) Улучшенные способы лечения васкуляризированных злокачественных опухолей
JP2019535670A5 (enExample)
JP2014509510A5 (enExample)
ME02148B (me) Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje
JP2018504105A5 (enExample)
JP2014158469A5 (enExample)
JP2018507188A5 (enExample)
JP2017529838A5 (enExample)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2017506067A5 (enExample)
JP2013527762A5 (enExample)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2014522850A5 (enExample)